Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16472260 | 1.00 | TSHR (0.33) | TSHRACHECYP2D6SMN1; SMN2MEN1 | |
| SCHEMBL12384592 | 0.82 | TSHR (0.41) | TSHRACHECYP2D6SMN1; SMN2MEN1 | |
| SCHEMBL16472292 | 0.82 | POLB (0.33) | TSHR | |
| SCHEMBL16478638 | 0.79 | ACHE (0.39) | TSHRACHESMN1; SMN2 | |
| SCHEMBL16472376 | 0.79 | ACHE (0.39) | TSHRACHESMN1; SMN2 | |
| SCHEMBL24634254 | 0.79 | ACHE (0.39) | TSHRACHESMN1; SMN2 | |
| SCHEMBL16587740 | 0.75 | TSHR (0.31) | TSHRCYP2D6SMN1; SMN2 | |
| SCHEMBL8077317 | 0.73 | TSHR (0.37) | TSHRACHECYP2D6SMN1; SMN2MEN1 | |
| SCHEMBL16587755 | 0.72 | JAK1 (0.30) | — | |
| SCHEMBL21597575 | 0.70 | ACHE (0.32) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220242859-A1 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242859-A1 | INHIBITORS OF SARM1 | SARM1, SMN1; SMN2, ADRM1 | TSHR 4495/4885ACHE 834/4885CYP2D6 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.